Candriam SCA
ARQT icon

Candriam SCA’s Arcutis Biotherapeutics ARQT Stock Holding History

Candriam SCA’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.6M Buy
1,003,729
+53,890
+6% +$1.41M 0.12% 164
2026
Q2 		$24.9M Sell
949,839
-136,812
-13% -$3.19M 0.11% 172
2026
Q1 		$25.6M Buy
1,086,651
+283,513
+35% +$7.24M 0.13% 164
2025
Q4 		$23.3M Buy
803,138
+25,094
+3% +$642K 0.12% 175
2025
Q3 		$14.7M Sell
778,044
-12,391
-2% -$195K 0.08% 217
2025
Q2 		$11.1M Sell
790,435
-245,141
-24% -$3.44M 0.06% 236
2025
Q1 		$16.2M Sell
1,035,576
-6,568
-0.6% -$92.5K 0.1% 182
2024
Q4 		$14.5M Sell
1,042,144
-384,352
-27% -$4.21M 0.08% 212
2024
Q3 		$13.3M Buy
1,426,496
+119,015
+9% +$1.17M 0.08% 233
2024
Q2 		$12.2M Buy
+1,307,481
New +$11.8M 0.07% 232

Other funds holding ARQT

Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Jay A. Fishman Ltd
Jay A. Fishman Ltd Troy, Michigan $1.24B AUM 21.21% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Fulcrum Asset Management
Fulcrum Asset Management London, United Kingdom $2.14B AUM 54.66% 1-Year Est. Return

Candriam SCA's ARQT Position: Q3 2026 in Review

Candriam SCA increased its Arcutis Biotherapeutics (ARQT) stake by 5.7% in Q3 2026, buying an estimated $1.41M and bringing the position to 1,003,729 shares worth $26.6M. The position accounts for 0.12% of the portfolio, ranked #164.

Candriam SCA first reported a position in ARQT in Q2 2024 and has held it in 10 quarters since. 88 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Candriam SCA held 1,003,729 shares of Arcutis Biotherapeutics worth $26.6M as of Q3 2026.
  • Candriam SCA bought 53,890 Arcutis Biotherapeutics shares in Q3 2026, an estimated $1.41M.
  • Arcutis Biotherapeutics made up 0.12% of Candriam SCA's portfolio in Q3 2026, its #164 holding.
  • Candriam SCA first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 10 quarters since.
  • 88 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.